Quick Answer
CRISPR Therapeutics AG reported Operating Income Loss of -$664.57 million for the year ending 2025.
- CRISPR Therapeutics AG showed a decrease of -42.4% in Operating Income Loss from 2024 to 2025.
- This data is from CRISPR Therapeutics AG's annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), CRISPR Therapeutics AG's Operating Income Loss has declined by 9,928.2%.
- Historical annual values: Fiscal year 2025: -$664.57 million | Fiscal year 2024: -$466.57 million | Fiscal year 2023: -$222.54 million | Fiscal year 2022: -$673.16 million | Fiscal year 2021: $373.53 million | Fiscal year 2020: -$354.44 million | Fiscal year 2019: $46.74 million | Fiscal year 2018: -$158.94 million | Fiscal year 2017: -$64.65 million | Fiscal year 2016: -$68.13 million | Fiscal year 2015: -$25.73 million | Fiscal year 2014: -$6.63 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: